---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-208858"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2022-08-01T23:59:59+00:00"
generated_at: "2026-06-24T06:28:46.328270+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Acumen presents ADDL assay method to standardize AßO testing for Alzheimer's therapeutics

## Summary
- Presented poster at AAIC 2022 on using ADDLs as synthetic AßO reference standard for bioanalytical assays.
- ADDL model addresses low concentration, instability, and heterogeneity of sAßOs in Alzheimer's brain.
- ACU193 Phase 1 trial ongoing; poster supports understanding of oligomer role in Alzheimer's disease.
- Panel of sAßO-targeting antibodies showed variable immunoreactivity with ADDLs; 20C2 selective over monomers.

## SEC filing metadata
- accession: 0001193125-22-208858
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2022-08-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000119312522208858/0001193125-22-208858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000119312522208858/d690801d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-208858
- JSON: https://secwatch.observer/filing/0001193125-22-208858.json
- Plain text: https://secwatch.observer/filing/0001193125-22-208858.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.